Senate Bill Could Eliminate Potential Access Barrier for Biosimilars
The Senate companion to last year’s 21st Century Cures Act could help biosimilars bypass a potential roadblock to patient access.
As Hepatitis C Deaths Peak, New York Removes Barriers to Cure
Just as new data shows hepatitis C deaths at an all-time high, New York state has taken a bold move to make curative treatments more available.
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Infant Health Bulletin Offers “Fast Facts” on Pregnant Women and Fish Consumption
Sensationalized media accounts have misconstrued the facts on pregnancy and fish consumption, explains a new Fast Facts health bulletin from the National Coalition for Infant Health.
Part B Demonstration Lacks Patient Monitoring Strategy, Says New Study
The Medicare Part B payment demonstration planned by the Centers for Medicare and Medicaid Services lacks a vital component: a clear strategy for monitoring the experiment’s effect on patient care.
New Study: Medicare Fix Could Require Seniors to Pay More for Biosimilars
by Amanda Conschafter, blog editor Government efforts to close Medicare Part D’s so-called donut hole could have unexpected consequences, explains a new study from Avalere Health. The Affordable Care Act now requires manufacturers to discount by 50 percent drugs purchased by Medicare beneficiaries in the coverage gap. Yet the requirement excludes generic drugs and biosimilars. The ironic result: Some […]
Telehealth Bill Could Improve Access to Care for Patients with Chronic Conditions
A bipartisan bill from the U.S. House of Representatives might help seniors better manage chronic conditions.
Patient Advocates Urge Congress to Act on National Pain Strategy
A new plan to address chronic pain has garnered overwhelming support from patient advocates.
AfPA Biologics Summit Highlights Need for Patient Safety, Informed Physicians
The Food and Drug Administration’s role is to determine a follow-on drug’s biosimilarity to its biologic predecessor, explained FDA’s Steven Kozlowski, MD, at Tuesday’s National Policy & Advocacy Summit on Biologics and Biosimilars.
The Alliance for Patient Access Calls for “Informed Drug Pricing”
A physician tells a story in the Alliance for Patient Access’ oncology working group white paper about attending the funeral of one of his cancer patients.
